^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BYON3521

    i
    Other names: BYON3521
    Company:
    Byondis
    Drug class:
    DNA replication inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    11ms
    Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate. (PubMed, Mol Cancer Ther)
    In all, our nonclinical data suggests that BYON3521 is a safe ADC with potential for clinical benefit in patients. A first-in-human dose escalation study is currently ongoing to determine the maximum tolerated dose and recommended dose for expansion (NCT05323045).
    Preclinical • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
    |
    MET amplification • MET expression
    |
    BYON3521
    1year
    First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521 (AACR 2023)
    To date, BYON3521 is well-tolerated with no DLTs at the investigated dose levels. Patient enrollment is ongoing and updated safety, efficacy and pharmacokinetic data will be presented. After the dose-escalation phase the trial will continue with expanded cohorts of patients with specific c-MET expressing cancer types.
    P1 data
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET positive
    |
    BYON3521
    2years
    A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (clinicaltrials.gov)
    P1, N=120, Recruiting, Byondis B.V.
    New P1 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET positive
    |
    BYON3521